Pure Financial Advisors Inc. Has $671,000 Position in Allergan PLC. (AGN)
Pure Financial Advisors Inc. maintained its stake in shares of Allergan PLC. (NYSE:AGN) during the second quarter, according to its most recent filing with the SEC. The firm owned 2,761 shares of the company’s stock at the end of the second quarter. Pure Financial Advisors Inc.’s holdings in Allergan PLC. were worth $671,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of AGN. Columbus Circle Investors acquired a new stake in shares of Allergan PLC. during the first quarter valued at approximately $3,937,000. Alta Capital Management LLC boosted its stake in shares of Allergan PLC. by 7.2% in the first quarter. Alta Capital Management LLC now owns 161,688 shares of the company’s stock valued at $38,630,000 after buying an additional 10,834 shares during the period. Feltz Wealth PLAN Inc. acquired a new stake in shares of Allergan PLC. during the first quarter valued at approximately $107,000. Nisa Investment Advisors LLC boosted its stake in shares of Allergan PLC. by 12.9% in the first quarter. Nisa Investment Advisors LLC now owns 95,746 shares of the company’s stock valued at $22,876,000 after buying an additional 10,903 shares during the period. Finally, Bank of The West boosted its stake in shares of Allergan PLC. by 11.5% in the first quarter. Bank of The West now owns 19,937 shares of the company’s stock valued at $4,763,000 after buying an additional 2,054 shares during the period. 83.63% of the stock is owned by institutional investors and hedge funds.
Allergan PLC. (AGN) traded up 0.16% during trading on Friday, hitting $225.12. The stock had a trading volume of 787,095 shares. The company has a market capitalization of $75.26 billion, a price-to-earnings ratio of 6.86 and a beta of 1.16. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80. The stock has a 50 day moving average price of $243.88 and a 200 day moving average price of $238.60.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the prior year, the business posted $3.35 EPS. The company’s quarterly revenue was up 8.8% on a year-over-year basis. Equities research analysts forecast that Allergan PLC. will post $16.27 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.25%. Allergan PLC.’s dividend payout ratio is 9.95%.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/18/pure-financial-advisors-inc-has-671000-position-in-allergan-plc-agn.html.
Several analysts have recently commented on the company. Mizuho reaffirmed a “buy” rating and issued a $267.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 price objective on Allergan PLC. and gave the company a “buy” rating in a research report on Thursday, August 3rd. Wells Fargo & Company lifted their price objective on Allergan PLC. to $278.00 and gave the company an “outperform” rating in a research report on Thursday, August 3rd. Deutsche Bank AG reissued a “buy” rating and set a $273.00 price objective (up previously from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Finally, Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price objective for the company in a research report on Monday, June 26th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the company. Allergan PLC. has a consensus rating of “Buy” and an average price target of $275.49.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.